Page 220 - Aet News Today

Amgen’s Lumakras became the first FDA-approved drug that addresses the elusive KRAS mutation, but Mirati believes its newly approved therapy, Krazati, could be better. The small molecule’s features include the ability to penetrate into the brain, where it can address cancer that has spread to the central nervous system.

Sanofi submitted the first unsolicited offer to acquire Horizon Therapeutics, but Amgen ultimately won what became a competitive bidding process. Amgen says Horizon's drug lineup complements its own portfolio of autoimmune and inflammatory disorder products.  

One technology that has tremendous potential to both broaden and improve access to preventive healthcare is wearable biosensing — more specifically, the continuous, non-invasive monitoring of multiple biomarkers from a smartwatch or wristband.

It may take some time to introduce VR into your skilled nursing facility, but it will be worth it for the physical, mental, and social benefit of your residents.

Each of us gets one life, and every life contains its own death. Engage with that fuller picture, wield hope carefully, and then, from everything this hospice doctor has seen, you will be OK, made whole by the time death rolls around, rather than pulled apart by it.

The Covid-19 pandemic has forced life sciences companies to take a fresh look at how they do business. But as they reinvent their operations, companies often overlook a critical function: Their learning and development programs.

Software company Feedtrail recently launched a clinician retention workgroup designed to streamline the process of connecting employees to positive patient feedback. The first cohort involves four providers, including Cedars-Sinai in Los Angeles and Huntington Hospital in Pasadena.

Johnson & Johnson is seeking FDA approval of a multiple myeloma drug that could become the first one addressing a novel target called GPRC5D. Data from the Phase 1/2 study supporting the biologics license application were presented in New Orleans during the annual meeting of the American Society of Hematology.

Avenda Health, a startup focused on personalized prostate cancer care, recently received 510(k) clearance from the FDA for its cancer mapping platform. The platform uses a patient’s own diagnostic data to define the extent of the disease and create a cancer probability map with optimal treatment margins.

Health benefit costs increased 3.2% in 2022, but employers are expecting costs to jump even higher in 2023, a Mercer report showed. Employers' top priorities right now are providing benefits that attract and retain employees and boosting mental health support.